Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
68 stocks in the US match these filters · market cap, largest first. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | Rare disease | $1.95B | $33.90 | −26.30% | −8.30% |
| SEPN | Septerna, Inc. | Rare disease | $1.93B | $41.30 | −19.18% | +23.32% |
| ETON | Eton Pharmaceuticals, Inc. | Rare disease | $1.80B | $63.05 | −5.00% | +49.02% |
| ANIP | ANI Pharmaceuticals, Inc. |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $1.74B |
| $75.65 |
| −23.97% |
| −3.47% |
| ANAB | AnaptysBio, Inc. | Rare disease | $1.73B | $58.37 | −19.33% | +8.88% |
| AVLN | Avalyn Pharma Inc. | Rare disease | $1.69B | $38.20 | −4.90% | +38.31% |
| 0L35.L | Sarepta Therapeutics, Inc. | Rare disease | $1.69B | $18.94 | −25.26% | +3.95% |
| MAZE | Maze Therapeutics, Inc. | Rare disease | $1.69B | $30.42 | −43.30% | +6.03% |
| FBRX | Forte Biosciences, Inc. | Rare disease | $1.63B | $76.97 | −0.30% | +0.61% |
| TRAX | First Tracks Biotherapeutics, Inc. | Rare disease | $1.61B | $45.11 | −9.62% | +7.33% |
| XERS | Xeris Biopharma Holdings, Inc. | Rare disease | $1.59B | $8.74 | −13.29% | +6.46% |
| TYRA | Tyra Biosciences, Inc. | Rare disease | $1.59B | $26.69 | −34.34% | −14.07% |
| A2RR34.SA | Arrowhead Pharmaceuticals, Inc. | Rare disease | $1.51B | 58.02 BRL | −3.22% | +4.58% |
| KALV | KalVista Pharmaceuticals Inc | Rare disease | $1.44B | $27.00 | 0.00% | 0.00% |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | Rare disease | $1.40B | $26.69 | −35.69% | +3.33% |
| OMER | Omeros Corporation | Rare disease | $1.40B | $19.28 | −1.88% | +70.02% |
| JBIO | Jade Biosciences, Inc. | Rare disease | $1.39B | $21.84 | −22.00% | +9.47% |
| 0HB0.L | Agios Pharmaceuticals, Inc. | Rare disease | $1.19B | $33.99 | −25.81% | +2.11% |
| SVRA | Savara Inc. | Rare disease | $1.15B | $5.60 | −20.06% | +3.13% |
| AVTX | Avalo Therapeutics, Inc. | Rare disease | $1.06B | $19.74 | −18.67% | +1.23% |
| WVE | Wave Life Sciences, Inc. | Rare disease | $1.03B | $5.25 | −75.84% | −11.32% |
| CLYM | Climb Bio Inc | Rare disease | $1.02B | $17.84 | −2.67% | +39.48% |
| DSGN | Design Therapeutics, Inc. | Rare disease | $981.28M | $15.68 | −9.10% | +31.99% |
| ANNX | Annexon, Inc. | Rare disease | $976.33M | $5.15 | −28.27% | +0.39% |
| STTK | Shattuck Labs, Inc. | Rare disease | $792.87M | $8.06 | −3.24% | +14.49% |
| TECX | Tectonic Therapeutic, Inc. | Rare disease | $737.21M | $37.71 | −4.60% | +23.20% |
| IRWD | Ironwood Pharmaceuticals, Inc. | Rare disease | $725.40M | $4.39 | −24.05% | +12.28% |
| ASMB | Assembly Biosciences, Inc. | Rare disease | $718.32M | $35.33 | −11.03% | +36.36% |
| ZVRA | Zevra Therapeutics, Inc. | Rare disease | $714.98M | $12.04 | −19.92% | +24.00% |
| GYRE | Gyre Therapeutics, Inc. | Rare disease | $682.86M | $6.68 | −29.09% | +8.97% |
| CRMD | CorMedix Inc. | Rare disease | $667.20M | $8.56 | −42.78% | +12.63% |
| ZURA | Zura Bio Limited | Rare disease | $605.64M | $6.32 | −15.05% | +17.47% |
| AQST | Aquestive Therapeutics, Inc. | Rare disease | $602.46M | $5.08 | −32.72% | +36.19% |
| 0KBU.L | Omeros Corporation | Rare disease | $575.28M | $19.34 | −1.41% | −0.10% |
| SPRY | ARS Pharmaceuticals, Inc. | Rare disease | $568.84M | $5.72 | −62.09% | −0.69% |
| QTTB | Q32 Bio Inc. | Rare disease | $485.84M | $16.32 | −30.76% | +7.30% |
| RZLT | Rezolute, Inc. | Rare disease | $482.42M | $5.01 | −56.27% | +1.42% |
| AVIR | Atea Pharmaceuticals, Inc. | Rare disease | $441.93M | $5.43 | −15.81% | +12.66% |
| LRMR | Larimar Therapeutics, Inc. | Rare disease | $432.15M | $4.16 | −35.20% | +8.62% |
| XFOR | X4 Pharmaceuticals, Inc. | Rare disease | $412.45M | $4.16 | −13.87% | +5.58% |
| ENTA | Enanta Pharmaceuticals, Inc. | Rare disease | $410.67M | $14.08 | −17.90% | +10.60% |
| UPB | Upstream Bio, Inc. | Rare disease | $393.26M | $7.18 | −78.68% | +12.19% |
| IKT | Inhibikase Therapeutics, Inc. | Rare disease | $348.84M | $2.50 | −1.57% | +6.38% |
| TRDA | Entrada Therapeutics, Inc. | Rare disease | $296.70M | $7.62 | −53.68% | +25.33% |
| TTRX | Turn Therapeutics Inc. | Rare disease | $295.48M | $9.73 | −63.28% | +25.06% |
| FULC | Fulcrum Therapeutics, Inc. | Rare disease | $294.51M | $3.86 | −75.48% | +3.49% |
| SION | Sionna Therapeutics, Inc. | Rare disease | $282.58M | $6.25 | −88.63% | −86.23% |
| ELDN | Eledon Pharmaceuticals, Inc. | Rare disease | $281.98M | $3.47 | −24.57% | −2.80% |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | Rare disease | $279.25M | $4.45 | −42.58% | +30.12% |
| IVVD | Invivyd, Inc. | Rare disease | $277.81M | $0.94 | −69.42% | +53.89% |
| AKBA | Akebia Therapeutics, Inc. | Rare disease | $265.58M | $0.96 | −71.13% | −25.12% |
| 0T6G.L | Q32 Bio Inc. | Rare disease | $246.69M | $16.27 | −30.78% | +4.95% |
| RNA | Prosensa Holding B.V. Ordinary Shares | Rare disease | $239.48M | $14.00 | −16.52% | +21.00% |
| PEPG | PepGen Inc. | Rare disease | $237.21M | $3.43 | −56.09% | +80.26% |
| KROS | Keros Therapeutics, Inc. | Rare disease | $213.74M | $11.68 | −48.20% | +14.40% |
| ANTX | AN2 Therapeutics, Inc. | Rare disease | $213.59M | $5.66 | −21.28% | +14.81% |
| SIGA | SIGA Technologies, Inc. | Rare disease | $211.24M | $3.04 | −67.83% | −1.94% |
| ARMP | Armata Pharmaceuticals, Inc. | Rare disease | $206.73M | $5.56 | −65.97% | +7.96% |
| PLX | Protalix BioTherapeutics, Inc. | Rare disease | $193.37M | $2.41 | −24.45% | +0.42% |
| SPRB | Spruce Biosciences, Inc. | Rare disease | $182.21M | $63.40 | −73.58% | +50.99% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.